ribupatide
ribupatide: sourced relationships with 1 company · 6 clinical trials tracked.
ribupatide evidence translation
What we can confirm
6 tracked trials
What it means
What to watch
Prepared research question
How could ribupatide → KLRA affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence5 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Kailera Therapeutics, Inc. (KLRA) End Stage Renal Disease; Obesity; Obesity With Diabetes | Phase 3 |
Clinical Trial Registry Records (6)
A Phase 1, Open Label, Parallel Group Study to Evaluate the Impact of Renal Impairment on the Pharmacokinetics of Ribupatide in Healthy Participants and in Participants Living With Severe Renal Impairment or End Stage Kidney Disease
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Ribupatide
A Multicenter, Randomized, Double-blind, Placebo-parallel-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Ribupatide Injection in Participants With Obesity and Knee Osteoarthritis
Primary endpoint: Change from baseline in WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) pain score after 68 weeks of treatment
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes
Primary endpoint: Percent Change From Baseline in Body Weight at Week 48
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
Primary endpoint: Doses 3 and 4 of Ribupatide Versus Placebo: Percent Change From Baseline in Body Weight at Week 76
A Phase 3, Randomized, Active- and Placebo-Controlled, Partially-Blinded Study to Compare the Efficacy and Safety of KAI-9531 Administered Once Weekly Versus Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
Primary endpoint: Percent Change From Baseline in Body Weight at Week 76
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
Primary endpoint: Dose 3 and 4 versus Placebo: Percent Change From Baseline in Body Weight at Week 76
Frequently asked questions
Which companies have sourced relationships with ribupatide?
ribupatide has dated SEC/FDA relationship records for Kailera Therapeutics, Inc..
How many clinical trials involve ribupatide?
BioSniper tracks 6 clinical trials involving ribupatide.